Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.


TSX:CPH - Post by User

Post by pabalooon Jan 11, 2021 9:44am
143 Views
Post# 32266053

No Generic Launch!

No Generic Launch!
Absorica and Absorica LD prescriptions – With looming threat of generic substitution, Sun has
been able to convert 27% of the Absorica prescriptions to Absorica LD. 

This is as of December 10, 2021. The pie will get very small for any generic soon as all scripts will be switched to the LD version which is safer and has a much higher absorption rate. I can't see any reason for a generic launch at this point Sun did a great job of keeping there own market. Now they need to start marketing this product to increase there share. They can easily hold double what they hold now. 

<< Previous
Bullboard Posts
Next >>